Together, these data suggest that L1CAM is required for maintaining the growth and survival of CD133+ glioma cells both in vivo and in vitro, and L1CAM may represent a GSC specific therapeutic target for improving the treatment of glioblastoma and possibly other brain tumors. This evidence concerns the gene L1CAM and glioblastoma.